JPRN-UMIN000014161
Completed
未知
Inhibitory efficacy in platelet aggregation and pharmacokinetics of single oral administration of 300mg clopidogrel and 20mg prasugrel - Inhibitory efficacy in platelet aggregation and pharmacokinetics of clopidogrel and prasugrel
Kazuo Umemura Center for clinical research Hamamatsu University Hospital0 sites50 target enrollmentAugust 1, 2014
ConditionsIschemic heart diseases with PIC
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Ischemic heart diseases with PIC
- Sponsor
- Kazuo Umemura Center for clinical research Hamamatsu University Hospital
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.History of liver diseases, cardiovascular diseases, respiratory diseaases, gastroenteric diseases, kidney diseases, cerebralvascular diseases, cancer 2\.Known hypersensitivity to some drugs and foods 3\.Under normal range in platelet counts at screning 4\.Treatment by other doctors (included supplement) within 14 days before screening 5\.Treatment with any investigational compound within 120 days before screening 6\.History of blood taken \*\>\= 1200ml of all blood within 1 year before screening \*\>\= 400ml of all blood with 84 days before screening \*\>\= 200ml of all blood within 14 days before screening 7\.Known active chronic hepatitis B or C, active syphilis and human immunodeficiency virus infection 8\.Abuse of alcohol or drugs (included past history) 9\.Bleeding, in the tendency to bleeding, and family history and past history of bleeding disorders 10\.During pregnancy and possibility of pregnancy and lactation period 11\.Any serious medical or psychiatric illness that could, in the opinion of the investigator, potentially interfere with the completion of treatment according to this protocol.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
The magnitude of platelet inhibition and the pharmacokinetics of a 600 mg loading dose of clopidogrel, in different patient categories (stable angina versus acute-coronary syndromes versus ST-elevated myocardial infarction).patients with a history of a stent thrombosis1003553410011082NL-OMON33697Cardiology200
Completed
Phase 4
ASsesment of Platelet function and Inhibition in patients Recovering from severe INfectionAcute myocardial infarctionHeart attack10011082NL-OMON50157Vrije Universiteit Medisch Centrum97
Active, not recruiting
Phase 1
Evaluation of platelet activity in patients recovering from a severe infectioHyperaggregability of thrombocytes triggered by severe infection (i.e. pneumonia or invasive urinary tract infection or a cutaneous infection).Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-004303-32-NLVU university medical center62
Active, not recruiting
Not Applicable
Effect of three different ticagrelor loading dose formulations (crushed, chewed or intact tablets) on the degree and rapidity of platelets ability to clump together and form clots in patients with stable angina referred for coronary angiographyEUCTR2014-002227-96-SECounty Council of Östergötland
Not yet recruiting
Phase 3
To compare platelet inhibition with crushed versus whole tablet administration of clopidogrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous intervention procedure.Health Condition 1: I22- Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarctionCTRI/2020/06/025647Fluid Research Fund